HC Wainwright & Co. Reiterates Buy on Denali Therapeutics, Maintains $95 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Denali Therapeutics (NASDAQ:DNLI) and maintained a $95 price target.

May 08, 2024 | 1:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Denali Therapeutics maintains a Buy rating and a $95 price target from HC Wainwright & Co.
The reiteration of a Buy rating and maintenance of a $95 price target by a reputable analyst firm like HC Wainwright & Co. typically signals a positive outlook on the stock, suggesting potential upside. This endorsement could lead to increased investor confidence in DNLI, potentially driving up its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100